NCT07140146 Trehalose vs Glycine Air-Polishing in Peri-Implant Mucositis Treatment
| NCT ID | NCT07140146 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pavia |
| Condition | Peri-implant Mucositis |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-08-30 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-08-30 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled clinical trial investigates the effectiveness of trehalose powder compared to glycine powder when used in air-polishing during supportive therapy for peri-implant mucositis, a reversible inflammatory condition affecting the soft tissues around dental implants. A total of 40 adult patients with peri-implant mucositis will be enrolled and randomly assigned to receive non-surgical periodontal therapy combined with air-polishing using either trehalose powder (test group) or glycine powder (control group). Clinical parameters will be evaluated at baseline, 1 month, 3 months, and 6 months. These include Plaque Index (PI), Bleeding on Probing (BoP), Probing Pocket Depth (PPD), and Bleeding Score (BS), in order to assess plaque accumulation, inflammation, and bleeding. The primary objective is to compare the reduction in plaque levels between the two groups over the study period. Secondary outcomes include evaluation of changes in gingival inflammation and probing depths, as well as assessment of implant surface integrity through in vitro scanning electron microscopy (SEM) after treatment. The aim of the study is to determine whether trehalose powder offers improved clinical outcomes and greater implant surface preservation compared to glycine powder in the non-surgical management of peri-implant mucositis.
Eligibility Criteria
Inclusion Criteria: * Adults aged between 18 and 70 years * Presence of peri-implant mucositis, defined as bleeding on probing (BoP) around implants without radiographic evidence of bone loss beyond initial remodeling * Visible biofilm on implant surfaces * Ability to understand and sign informed consent * Good oral hygiene and patient compliance * Availability for all follow-up visits (1, 3, and 6 months) Exclusion Criteria: * Presence of systemic conditions that may affect healing (e.g., uncontrolled diabetes, immunosuppression) * Current smokers or former smokers who quit less than 6 months ago * Pregnant or breastfeeding women * Use of antibiotics or anti-inflammatory drugs in the 3 months prior to baseline * Presence of peri-implantitis (i.e., bleeding on probing with concomitant radiographic bone loss) * History of head and neck radiotherapy * Presence of pacemakers or cardiac stimulators * Neurological or psychological disorders affecting study compliance
Contact & Investigator
Andrea Scribante, Associate Professor
PRINCIPAL INVESTIGATOR
University of Pavia
Frequently Asked Questions
Who can join the NCT07140146 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Peri-implant Mucositis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07140146 currently recruiting?
Yes, NCT07140146 is actively recruiting participants. Contact the research team at andrea.scribante@unipv.it for enrollment information.
Where is the NCT07140146 trial being conducted?
This trial is being conducted at Pavia, Italy.
Who is sponsoring the NCT07140146 clinical trial?
NCT07140146 is sponsored by University of Pavia. The principal investigator is Andrea Scribante, Associate Professor at University of Pavia. The trial plans to enroll 40 participants.